Literature DB >> 12030807

Elevation of atrial natriuretic peptide levels in aqueous humor of the rabbit by kappa opioid receptor agonists.

K R Russell1, T T Moore, D E Potter.   

Abstract

Following the topical administration of three kappa agonists (bremazocine, spiradoline and ICI 204448) to rabbit eyes, aqueous humor samples were analyzed for levels of atrial natriuretic peptide (ANP). Bremazocine (BRE) and spiradoline (SPR) elevated aqueous ANP levels in a dose-dependent manner. In contrast, ICI had no significant effect on ANP levels in aqueous humor. Nor-binaltorphimine (nor-BNI), a selective kappa opioid receptor antagonist, was used to assess kappa opioid receptor involvement and glibenclamide, an ATP-sensitive K+ channel blocker, was used to test for the role of ATP-sensitive potassium channels in ANP release. Pretreatment with nor-BNI antagonized the increases in ANP levels observed with both BRE and SPR. Likewise, glibenclamide suppressed the stimulation of ANP secretion by bremazocine. In summary, BRE and SPR increased ANP levels in aqueous humor of rabbits, in part, via activation of K+(ATP) channels that are assumed to be associated with kappa opioid receptors. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12030807     DOI: 10.1054/npep.2001.0883

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  3 in total

1.  Kappa opioid receptor localization and coupling to nitric oxide production in cells of the anterior chamber.

Authors:  Karen R Russell-Randall; Juanita Dortch-Carnes
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-13       Impact factor: 4.799

2.  Aqueous humor dynamics in monkeys in response to the kappa opioid agonist bremazocine.

Authors:  Carol A Rasmussen; B'Ann True Gabelt; Paul L Kaufman
Journal:  Trans Am Ophthalmol Soc       Date:  2007

3.  Characterization of intraocular pressure responses of the Tibetan monkey (Macaca thibetana).

Authors:  Guo Liu; Tao Zeng; Wenhan Yu; Naihong Yan; Hongxing Wang; Su-ping Cai; Iok-Hou Pang; Xuyang Liu
Journal:  Mol Vis       Date:  2011-05-27       Impact factor: 2.367

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.